<< Вернуться к списку статей журнала

Том 7 №2 2005 год - Нефрология и диализ

Эффективность и токсичность циклоспорина А. Мониторинг концентрации (Обзор литературы)

Вознесенская Т.С.

Аннотация: Циклоспорин А хорошо известен как эффективный иммуносупрессивный препарат, используемый в течение последних 15 лет при трансплантации органов [26, 39, 46]. С 1986 г. циклоспорин А применяется для лечения стероид-резистентного, стероид-зависимого и часторецидивирующего нефротического синдрома [5, 6, 18, 23, 43, 48, 51].

Для цитирования: Вознесенская Т.С. Эффективность и токсичность циклоспорина А. Мониторинг концентрации (Обзор литературы). Нефрология и диализ. 2005. 7(2):135-139. doi:

Весь текст

Ключевые слова: циклоспорин А, эффективность, токсичность, нефротический синдром, трансплантация

Список литературы:

1. Каабак М.М., Горяйнов В.А., Агуреева Л.И. и соавт. Выбор оптимального режима терапии циклоспорином у реципиентов аллогенных почек в различные сроки после операции. Нефрология и диализ 2001; 3: 57-60.
2. Столяревич Е.С., Суханов А.В., Багдасарян А.Р. и соавт. К вопросу об оптимизации мониторинга терапии препаратами циклоспорина в поздние сроки после аллотрансплантации почки. Нефрология и диализ 2004; 6: 145-154.
3. Amante A.J., Kahan B.D. Abbreviated area under the curve strategy for monitoring cyclosporin microemulsion therapy in immediate posttransplant period. Clin Chem 1996; 42: 1294-1296.
4. Cantarovich M., Besner J.G., Barkun J.S. et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249.
5. Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 1999; 56: 2220-2226.
6. Cattran D.C., Appel G.B., Hebert L.A. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001; 59: 1484-1490.
7. Churchill P.C., Rossi N.F., Churchill M.C. et al. Acute cyclosporine-induced renal vasoconstriction: lack effect of theophilline. Am J Phisiol 1990; 258: 41-45.
8. Clardy C.W., Schroeder T.J., Myre S.A. et al. Clinical variability of cyclosporine pharmacokinetics in adults and pediatric patients after renal, cardiac, hepatic and bone marrow transplants. Clin Chem 1988; 34: 2012-2015.
9. Dello Strologo L., Campagnano P., Federici G. et al. Cyclosporine A monitoring in children: abbreviated area under the curve formulars and C2 level. Pediatr Nephrol 1999; 13: 95-97.
10. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-495.
11. Feutren G., Mihatsch M. Risk factors for cyclosporine-induced nephrotoxicity in patients with autoimmune disease. N Engl J Med 1992; 326: 1654-1660.
12. Floren L.C., Bekersky I., Benet L.Z. et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-49.
13. Gregory M.J., Smoyer W.E., Sedman A. et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: A clinical and histologic analysis. J Am Soc Nephrol 1996; 7: 543-549.
14. Grevel J., Welsh M.S., Kahan B.D. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246-248.
15. Halloran P.F., Helms L.M.H., Kung L. et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
16. Hamahira K., Iijima K., Tanaka R. et al. Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome. Pediatr Nephrol 2001; 16: 723-727.
17. Hebert M.F., Roberts J.P., Prueksaritanont T. et al. Bioavailability of cyclosporine with concomitant rifampicin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
18. Hino S., Takemura T., Okada M. et al. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 1998; 31: 932-939.
19. Hoppu K., Koskimies O., Holmberg C. Evidence for pre-hepatic metabolism of oral cyclosporine in children. Br J Clin Pharmacol 1991; 32: 477-481.
20. Iijima K., Hamahira K., Tanaka R. et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002; 61: 1801-1805.
21. Iijima K., Hamahira K., Kobayashi A. et al. Immunohistochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome. J Am Soc Nephrol 2000; 11: 2265-2271.
22. Ingulli E., Singh A., Baqi N. et al. Aggressive, long-term cyclosporine therapy for steroid resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5: 1820-1825.
23. Inoue Y., Iijima K., Nakamura H. et al. Two-year cyclosporine treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1999; 13: 33-38.
24. Johnson D.W., Saunders H.J., Johnson F.J. et al. Cyclosporine exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta 1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999; 289: 535-542.
25. Kabasakul S.C., Clarke M., Kane H. et al. Comparison of Neoral and Sandimmun cyclosporine A pharmacokinetic profiles in young renal transplant recipients. Pediatr Nephrol 1997; 11: 318-321.
26. Kahan B.D. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
27. Kahan B.D. Cyclosporin nephrotoxicity: pathogenesis, prophylaxis, therapy and prognosis. Am J Kidney Dis 1986; 8: 323-331.
28. Kahan B.D., Dunn J., Fitts C. et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940-2943.
29. Kahan B.D., Kramer W.G., Wideman C. et al. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459-464.
30. Kahan B.D., Welsh M., Schoenberg L. et al. Variable oral absorption of cyclosporine: A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606.
31. Kasiske B.L., Heim-Duthoy K., Rao V. et al. The relationship between cyclosporine pharmacokinetics parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716-722.
32. Kelles A., Herman J., Tjandra-Maga T.B. et al. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 1999; 3: 282-287.
33. Kelles A., Van Damme-Lombaerts R., Tjandra-Maga T.B. et al. Long-term cyclosporine A pharmacokinetic profiles in pediatric renal transplant recipients. Transplant Int 1996; 9: 546-550.
34. Keown P., Landsberg D., Halloran P. et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral renal transplantation study group. Transplantation 1996; 62: 1744-1752.
35. Lin C.Y., Lee S.F. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients. Transplant Proc 1994; 26: 2973-2974.
36. Lindholm A., Welsh M., Alton C. et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patient with uremia: Racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359-371.
37. Melocoton T.L., Kamil E.S., Cohen A.H. et al. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependant nephrotic syndrome. Am J Kidney Dis 1991; 18: 583-588.
38. Messana J.M., Johnson K.J., Mihatsch M.J. Renal structure and function affects after low dose cyclosporine in psoriasis patients: a preliminary report. Clin Pathol 1995; 43: 180-183.
39. Mochon M., Cooney G., Lum B. et al. Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 1996; 36: 580-586.
40. Niaudet P., Broyer M., Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporine A in children. Clin Nephrol 1991; 35: S31-S36 (Suppl. 1).
41. Noble S., Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995; 50: 924-941.
42. Pei Y., Chan C., Cattran D. et al. Sustained vasoconstriction associated with daily cyclosporin dose in heart and lung transplant recipients: potential pathophysiologic role of endotelin. J Lab Clin Med 1995; 125: 113-119.
43. Ponticelli C., Rizzone G., Edefonti A. et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-1384.
44. Prevot A., Semama D.S., Justrabo E. et al. Acute cyclosporine A-induced nephrotoxicity: a rabbit model. Pediatr Nephrol 2000; 14: 385-388.
45. Savoldi S., Kahan B.D. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. Transplant Proc 1986; 18: 120-128.
46. Schnuelle P., Van Der Heide J.H., Tegzess A. et al. Open randomized trial comparing early withdrawal of either Cyclosporine or Mycophenolate Mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536-543.
47. Sindhi R., LaVia M.F., Pauling E. et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine ÷ rapamycin regimen. Transplantation 2000; 69: 432-436.
48. Singh A., Tejani C., Tejani A. One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 1999; 13: 26-32.
49. Strom E.H., Epper R., Mihasth M.J. Cyclosporine-associated arteriolopathy: The rennin producing vascular smooth muscle cells are more sensitive to cyclosporin toxicity. Clin Nephrol 1995; 43: 226-231.
50. Tam J.C., Earl J.W., Willis N.S. et al. Pharmacokinetics of cyclosporine in children with stable renal transplants. Pediatr Nephrol 2000; 15: 167-170.
51. Tejani A. Cyclosporine-induced remission of relapsing nephrotic syndrome in childhood (abstract). Kidney Int 1986; 29: 206.
52. Tejani A., Butt K.M.H., Trachtman H. et al. Cyclosporine-induced remission of childhood nephrotic syndrome. Kidney Int 1988; 33: 729-734.
53. Tejani A., Sullivan E.K. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: A report of the North American Renal Transplant Cooperative Study.
54. J Am Soc Nephrol 1996; 7: 550-555.
55. Von Moltke L.L., Greenblatt D.J., Schmider J. et al. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet 1995; 29: 33-44.
56. Wandstrat T.L., Schroeder T.J., Myre S.A. Cyclosporine pharmacokinetics in pediatric transplant recipients. Ther Drug Monit 1989; 11: 493-496.
57. Wolf G., Thaiss F., Stahl R.A. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900-905.
58. Wolf G., Thaiss F., Stahl R.A. Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects. Transplantation 1995; 60: 237-241.
59. Wu C.Y., Benet L.Z., Hebert M.F. et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497.
60. Yee G., Lennon T.P., Gmur M.S. et al. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438-443.
61. Zieste R., Derks F.H.M., Schalekamp A. et al. Cyclosporine and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. In: Tejani A. (ed). Cyclosporine in the therapy of renal disease. Karger, New York, 1995: 6-18.
62. Zimmerhackl L.B., Fretscher M., Steinhausen M. Cyclosporin reduces renal blood flow through vasoconstriction of arcuate arteries in the hydronephrotic rat model. Klin Wochenschr 1990; 68: 166-174.

Другие статьи по теме

• Опыт применения циклоспорина А в лечении идиопатического фокального сегментарного гломерулосклероза
• Применение сандиммуна-неорала в лечении нефротического синдрома при болезни минимальных изменений в сочетании с сахарным диабетом I типа (Обзор литературы и собственное наблюдение)
• Перитонеальный диализ в лечении хронической почечной недостаточности: достоинства, эффективность, проблемы длительного применения
• Применение циклоспорина а для лечения нефротических типов хронических гломерулонефритов - болезни минимальных изменений и фокального сегментарного гломерулосклероза